Pfizer’s Abrocitinib Quick Off The Mark In Atopic Dermatitis
Top-Line Results From Third Phase III Study
Pfizer’s next-generation JAK1 inhibitor, abrocitinib, continues to show beneficial effects in atopic dermatitis (eczema), in the JADE COMPARE study, comparable to the positive control dupilumab and, in the case of itch, with a faster onset at the higher dose.
You may also be interested in...
Amgen said Phase II data are planned for the EADV 2021 meeting, but KHK4083 will need a strong showing.
The company showed improvement on an endpoint used in several Phase III studies of JAK inhibitors, but with a potentially better safety profile.
It has gone under the radar that Eli Lilly and Incyte's Olumiant has recently become the first JAK inhibitor to be approved anywhere for atopic dermatitis and the companies have been touting promising long-term data on the therapy as it expands beyond rheumatoid arthritis.